Presence of Immunoreactive Endothelin-1 and Atrial Natriuretic Peptide in Human Pericardial Fluid

Horkay, Ferenc; Szokodi, István; Selmeci, L.; Merkely, Béla; Kékesi, Violetta; Vecsey, T; Vuolteenaho, Olli; Ruskoaho, Heikki; Juhász‐Nagy, Alexander; Tóth, Miklós

doi:10.1016/s0024-3205(97)01105-3

Cited by 28 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pericardial ET levels were higher as compared with plasma, corresponding to previous reports in different species such as rats, dogs and human beings. 2 Changes in the coronary sinus levels of ET were similar to the changes in plasma levels, whereas there was no change in the pericardial fluid ET levels, suggesting that the pericardial space is a functionally different compartment.…”

Section: Discussionmentioning

confidence: 64%

Endothelin Levels in Experimental Diabetes Combined with Cardiac Hypertrophy

Skoumal

Serés

Soós

et al. 2004

Journal of Cardiovascular Pharmacology

Self Cite

View full text Add to dashboard Cite

Diabetes mellitus is associated with endothelial and cardiac dysfunction, and endothelin has been suggested to alter cardiac function by being a positive inotropic agent, modulating the Frank-Starling response, contracting the coronary arteries and inducing tissue proliferation. We investigated endothelin levels in diabetic and in healthy dogs, 1 and 3 days after placing arteriovenous shunts (8 weeks after diabetes induction) in the femoral regions. Right and left ventricular weight/body weight ratios and Nterminal- atrial natriuretic peptide were increased in shunted animals (P < 0.05). Plasma endothelin levels were comparable in healthy and diabetic dogs. Shunted circulation did not change systemic endothelin levels in healthy dogs but reduced endothelin levels in diabetic dogs. The functional significance of altered endothelin responses to acute hemodynamic burden in experimental diabetes needs further investigation.

show abstract

Section: Discussionmentioning

confidence: 64%

Endothelin Levels in Experimental Diabetes Combined with Cardiac Hypertrophy

Skoumal

Serés

Soós

et al. 2004

Journal of Cardiovascular Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…40) It has been reported that ET-1 is present in canine, 41) sheep, 42) and human pericardial fluid. 43) A potential source of factors in the pericardial space is the circulating blood. However, it has been determined that the source of ET-1 in pericardial fluid is pericardial mesothelial cells and the myocardium.…”

Section: Discussionmentioning

confidence: 99%

Endothelin-1 Concentrations in Pericardial Fluid Are More Elevated in Patients with Ischemic Heart Disease Than in Patients With Nonischemic Heart Disease

et al. 2003

View full text Add to dashboard Cite

SUMMARYThere is epidemiologic evidence that the prognosis of patients with nonischemic heart failure is better than that for patients with ischemic heart failure. In addition, studies have revealed that patients with ischemic heart failure show a poorer response to medical therapy. However, the pathophysiologic difference between ischemic and nonischemic heart disease is unclear. To clarify this point, we measured atrial natriuretic peptide, brain natriuretic peptide, angiotensin II, endothelin (ET)-1, interleukin-1β, interleukin-6, tumor necrosis factor (TNF)-α, soluble TNF receptor I, and soluble TNF receptor II concentrations in plasma and pericardial fluid in patients with ischemic or nonischemic heart disease undergoing cardiac surgery. The pericardial ET-1 concentration in patients with ischemic heart disease was statistically greater than that in patients with nonischemic heart disease (about 1.5-fold), although no difference was found in the plasma ET-1 concentration. These findings suggest that the production and secretion of ET-1 from the myocardium in patients with ischemic heart disease are augmented to a greater extent than in patients with nonischemic heart disease. This result may lead to a greater understanding of the pathophysiology of ischemic heart disease. (Jpn Heart J 2003; 44: 633-644)

show abstract

“…[11][12][13] Notably, physiological concentrations of certain regulatory agents were found to be several magnitudes higher in the pericardial fluid than in the peripheral and coronary venous blood. 2,3,7,14,15 These elevated pericardial levels reflect their myocardial derivation and suggest a teleological role for the pericardial space as a functionally distinct compartment with potential (patho)physiological function in cardiac regulation. Moreover, the pericardial space offers the opportunity to examine the effects and interactions among the aforementioned agents, whose pericardial concentrations may be elevated in cardiovascular pathologies.…”

Section: Introductionmentioning

confidence: 97%

Comparison of Elimination and Cardiovascular Effects of Adenine Nucleosides Administered Intrapericardially or Intravenously in Anesthetized Dog

Nagy¹,

Sax²,

Entz³

et al. 2009

Journal of Cardiovascular Pharmacology

Self Cite

View full text Add to dashboard Cite

Intrapericardial (IP) administration of certain cardioactive agents allows investigation of local pharmacological actions on the heart and may carry potential benefit to influence myocardial function. The cardioprotective adenosine (ADO) and inosine (INO) may be the most representative candidates. Elimination and cardiovascular effects of IP and intravenously (IV) applied ADO and INO were compared on anesthetized dogs. Their pericardial and systemic concentrations were measured after consecutive administration of increasing ADO and INO doses. In the case of IP administration at the end of the incubation period, pericardial concentrations of adenine nucleosides significantly exceeded the control values. However, the IV applied ADO and INO were rapidly metabolized in the systemic plasma. As characteristic hemodynamic effects, small but sustained decrease in heart rate (IP ADO) and increase in myocardial contractility (IP INO) were observed. During IV administration, ADO and INO exerted remarkable effects on all hemodynamic variables, which then gradually disappeared in 15 minutes. In summary, the elimination of ADO and INO was significantly slower in the pericardial fluid than in the plasma. Considering the balanced cardiac actions and lack of strong systemic hemodynamic effects, IP administration of adenine nucleosides may suggest a promising approach in the local treatment of the diseased heart.

show abstract

Presence of Immunoreactive Endothelin-1 and Atrial Natriuretic Peptide in Human Pericardial Fluid

Cited by 28 publications

References 33 publications

Endothelin Levels in Experimental Diabetes Combined with Cardiac Hypertrophy

Endothelin Levels in Experimental Diabetes Combined with Cardiac Hypertrophy

Endothelin-1 Concentrations in Pericardial Fluid Are More Elevated in Patients with Ischemic Heart Disease Than in Patients With Nonischemic Heart Disease

Comparison of Elimination and Cardiovascular Effects of Adenine Nucleosides Administered Intrapericardially or Intravenously in Anesthetized Dog

Contact Info

Product

Resources

About